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A B S T R A C T
The aim of this retrospective study was to create guidelines for therapy of severe sepsis in surgical intensive care unit
(ICU) for unknown causative agent based on antimicrobial susceptibility of causative bacteria. Seventy-four patients
with severe sepsis from surgical ICU in 2003.–2005. were included in study. Their clinical and microbiological data
were analyzed from the medical records. Antimicrobial susceptibility of the strains isolated from the blood-culture was
tested by disk diffusion method according to CLSI (Clinical Laboratory Standard Institution). APACHE II score was
used to predict the severity of illness. Statistical significance difference between results was tested by Mann-Whitney test
and x2 test. Important problem remained type of sepsis: mono-agent sepsis presented less therapeutic problem than sepsis
caused with two or more agents (mixed sepsis). Methicillin-resistant Staphylococcus aureus (MRSA), Pseudomonas ae-
ruginosa and Acinetobacter baumannii were predominant causative agents in both type of sepsis. There was remarkable
increase of A. baumannii prevalence in 2005 compared to 2004 and to 2003. There was also decrease of MRSA prevalence
in 2004 and 2005 compared to 2003. P.aeruginosa were the predominant causative agents in 2004. MRSA displayed good
susceptibility to vancomycin and linezolide, whereas P. aeruginosa showed excellent susceptibility to ceftazidime and
carbapenems. A. baumannii, third predominant causative agent, exhibited excellent susceptibility to ampicillin+ sul-
bactam and carbapenems. The recommended therapy is empirical and should cover all important pathogens.
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Introduction
The mortality of sepsis, sever sepsis (infection-in-
duced organ dysfunction or hypoperfusion abnormali-
ties) and septic shock (hypotension not reversed with
fluid resuscitation and associated with organ dysfunction
or hypoperfusion abnormalities) in most ICU remains
unacceptably high1,2. In 2001, the International Sepsis
Forum published guidelines on the management of pa-
tients with severe sepsis and septic shock, including an
evidence-based review on antibiotic therapy3. In 2003,
under the auspices of the Surviving Sepsis Campaign,
critical care and infectious disease experts representing
11 international organizations, the International Sepsis
Forum published guidelines have been updated and ex-
tended4. Criteria for sepsis definition and antibiotic the-
rapy pattern are recommended until now.
Infection is sine qua non of sepsis and can occur at
any site, most commonly the respiratory tract, abdomen
and bloodstream3,4. More than 90% of cases of sepsis are
caused by bacteria, and Gram-negative and Gram-posi-
tive organisms occur with approximately equal frequen-
cy5. There are several reasons why it is important to ob-
tain a precise microbiological diagnosis in septic patients.
One, and most important, is to ensure that effective
antimicrobial therapy is given6.
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Choice of empirical antibiotic therapy depends on sev-
eral factors related to the patient’s history (including
drug intolerance), underlying diseases and susceptibility
patterns of microorganisms in the hospital environ-
ment7. The initial selection of an empirical antimicrobial
regimen, monotherapy or combination therapy, should
be broad enough to cover likely pathogens; for mixed
(polymicrobial) or one causative agent infection. Mixed
infections have been shown to pose a more serious thera-
peutic problem6,8. Choice of appropriate empirical antibi-
otic therapy in sepsis is one of the most important factors
for the better outcome of patients in sepsis3,8.
The aim of this paper is to define and suggest the ap-
propriate empirical antibiotic therapy in surgical inten-
sive care unit (ICU) in Clinical Hospital Center Zagreb.
Patients and Methods
Study population
The retrospective study was conducted in an 8-bed
surgical ICU at University hospital Center Zagreb,
Croatia. The study was included patients with sepsis
treated at ICU between January 1, 2003 and December
31, 2005. Of 2349 surgical ICU patients admitted during
study period, 74 had confirmed diagnosis of severe sepsis
with positive blood-culture (BC) in the records from the
clinical microbiology laboratory. Epidemiological, clinical
and microbiological data were analyzed from the medical
records of these 74 patients.
Identification and antimicrobial susceptibility
testing
Blood cultures were processed with the BACTEC sys-
tem and organisms were identified using Vitek system.
Results were interpreted according to the guidelines of
the Clinical Laboratory Standard Institution (CLSI). In-
termediate susceptibility to the antibiotics was consid-
ered as resistance.
Study design and data collection
The medical records of patients were retrospectively
reviewed. The clinical data collected included: age, gen-
der, severity of illness (as calculated by acute physiology
and chronic health evaluation – APACHE II score within
the first 24h of admission in ICU9), antimicrobial ther-
apy regimen at admission in ICU, changing of the ther-
apy according to disk diffusion test (antibiogram), in vi-
tro effectiveness of empirical antimicrobial agents, in
vitro effectiveness of definitive antimicrobial agents and
antimicrobial susceptibility of causative agents, type of
infection (caused by one agent or polymicrobial), type of
agents causing infection and outcome of patients.
Antibiotic therapy
Empirical antimicrobial therapy was initiated imme-
diately after diagnosis of sepsis was confirmed and blood
culture had been taken, and was changed to definitive
therapy according to the results of culture and suscepti-
bility testing within 3 days after the bacteriemia episode.
The choice of monotherapy vs. combined therapy which
was administered as definitive therapy was made by at-
tending physician.
Definitions
The standard definition for sepsis (severe sepsis and
septic shock) provided by the Internal Sepsis Forumwere
used to determine sepsis3,4. Severe sepsis was defined as
sepsis associated with evidence of at last one organ dys-
function and positive blood-culture. Mixed sepsis was de-
fined as the presence of two or more causative bacteria in
the blood-culture. Positive blood-culture (BC) was de-
fined as the isolation of the bacterial species from one or
more blood cultures, and by the presence of clinical fea-
tures consistent with sepsis.
Statistical analysis
Statistical significance difference between results was
tested by Mann-Whitney test and x2 test.
Results
A total of 74 patients with severe sepsis were included
in the present study. The mean age for all patients was 58
(range 22–85), 52 were male and 22 female. Forty-eight
(65%) patients had sepsis caused by one agent and 26
(35%) patients had polymicrobial (mixed) sepsis (Figure
1). Ten different causative agents were isolated, 9 agents
in mono-agent sepsis, and 10 agents in mixed sepsis
(Figures 2 and 3). MRSA, P. aeruginosa and A.baumannii
were the predominant causative agents in both type of
sepsis. P.aeruginosa was found in 27% (11) patients with
mono-agent sepsis and in 22% (14) patients showing
mixed sepsis whereas MRSA was found in 30% (12)
patients showing mono-agent sepsis and 22% (14)
patients having mixed sepsis.
A. baumanniiwas identified at 10% (4) patients show-
ing mono-agent sepsis and at 18% (12) patients with
mixed sepsis.
Coagulase-negative Staphylococcus, Staphylococcus
aureus, Klebsiella pneumoniae and Serratia marcescens
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Fig. 1. Types of sepsis.
were detected with equale frequency in 3% (1) patient
with mono-agent sepsis. At mixed sepsis coagulase-nega-
tive Staphylococcus and S. aureus were detected also at
4% (3) patients respectively, same as Enterobacter spe-
cies, whereas S. marcescens was at 2% (2) patients. K.
pneumoniae was identified at 10% (7) patients showing
mixed sepsis. Escherichia coli was found in 5(13%) pa-
tients with mono-agent sepsis and also at 5 (7%) patients
with mixed sepsis. Enterococcus faecalis was found in 8%
(3) patients with mono-agent sepsis and in 7% (5) pa-
tients with mixed sepsis.
The initial (empirical) antibiotic therapy was changed
in 52 (70%) patients, in spite of that 9 patients died. Ini-
tial antibiotic therapy was not changed in 22 (30%) pa-
tients 13 of them died. Total mortality rate was 30% (22
of 74 patients).
Average value of APACHE II score was 16, average
value of APACHE II score for patients who died was 22,
APACHE II score was higher in patients who died.
The predicted value of APACHE II score for mortality
was 40%, which correlated with total mortality of 30%.
Statistical analysis
There was statistically significant difference in APA-
CHE II score between patients who were successfully
treated and those who died (Mann-Whitney U-test, p=
0.002). No significant difference in APACHE II score was
found between patients who died with mono-agent sepsis
and mixed sepsis (p>0.05).
Antimicrobial therapy was significantly more often
changed according to antibiogram for younger patients
compared to the older patients (Mann-Whitney U-test,
p=0.027).
According to a causative agent correction of the ther-
apy was more often necessary for mixed sepsis (c2 test,
p=0.019).
Prevalence of bacterial isolates and
temporary trends
MRSA (25%) and P. aeruginosa (23%) were the most
prevalent bacterial isolates from the blood-culture fol-
lowed by A. baumannii (15%) and E. coli (9%) (Figure 4).
There were 7% isolates of E. faecalis and K. pneumoniae
and were 4% of coagulase-negative Staphylococcus and S.
aureus.
The least prevalent were Enterobacter spp. and S.
marcescens (3%). There was remarkable increase of A.
baumannii prevalence in 2005 (11 isolates) compared to
2004 (4 isolates) and to 2003 (1 isolate).There was also
decrease of MRSA prevalence in 2004 and 2005 (7 iso-
lates) compared to 2003 (12 isolates, Figure 5).
Antimicrobial susceptibility
100% of MRSA strains were susceptible to vanco-
mycin and rifampicin. Among P. aeruginosa no resistance
to ceftazidime, meropenem, colistin was observed. All A.
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Fig. 2. Bacterial isolates in mono-agent sepsis. AB – Acinetobac-
ter baumannii, EC – Escherichia coli, EF – Enterococcus faeca-
lis, ES – Enterobacter spp, KL –Klebsiella pneumoniae, MRSA –
Methicillin-resistant Staphylococcus aureus, PA – Pseudomonas
aeruginosa, SA – Staphylococcus aureus, SE – coagulase- nega-
tive Staphylococcus, SM – Serratia marcescens.
Fig. 3. Bacterial isolates in mixed sepsis. AB – Acinetobacter
baumannii EC – Escherichia coli, EF – Enterococcus faecalis,
ES – Enterobacter spp, KL –Klebsiella pneumoniae, MRSA –
Methicillin-resistant Staphylococcus aureus, PA – Pseudomonas
aeruginosa, SA – Staphylococcus aureus, SE – coagulase-nega-
tive Staphylococcus, SM – Serratia marcescens.
Fig. 4. Prevalence of bacterial isolates. AB – Acinetobacter bau-
mannii, EC – Escherichia coli, EF – Enterococcus faecalis, ES –
Enterobacter spp, KL –Klebsiella pneumoniae, MRSA – Methi-
cillin-resistant Staphylococcus aureus, PA – Pseudomonas aeru-
ginosa, SA – Staphylococcus aureus, SE – coagulase-negative
Staphylococcus, SM – Serratia marcescens.
baumannii strains were susceptible to ampicillin+sul-
bactam, imipenem, meropenem. All Enterobacteriaceae
(K. pneumoniae, Enterobacter spp. and E. coli) strains
were sensitive to ceftazidime, gentamicin, imipenem and
meropenem. Coagulase-negative Staphylococcus was sen-
sitive to ampicillin and cloxacillin. Enterococcus spp.
waere sensitive to ampicillin, vancomycin and rifam-
picin.
Discussion
The many recent studies report high frequency of sep-
sis, mortality rates, with 27% of patients dying in the
ICU, rising to more than 50% in patients with severe sep-
sis and septic shock5,10. We report higher mortality rate
of severe sepsis than in some other recent study; for ex-
ample, the EPISEPSIS study in France reported that
15% of patients had severe sepsis and UK study reported
a rate of 27%11. However, this study included patients ad-
mitted for routine postoperative surveillance who are
likely to have lower rates of complications. In contrast, in
our study more patients were admitted in emergency.
In spite of the all known guidelines and recommenda-
tion for treating, sepsis is still associated with significant
mortality and health-care costs1,12,13. Mortality rate ac-
cording to our results was 30%, which is in concordance
with the bibliographic data.
Furthermore, this proportion remains high in spite of
the new antimicrobial agents1,14.
Another important problem remained the type of sep-
sis: mono-agent sepsis presented less therapeutic prob-
lem than sepsis caused with two or more agent (mixed
sepsis). There was 35% mixed sepsis and 65% mono-
agent sepsis in our study. This is also correlated with the
data published by other autors6,14,15. We found no signifi-
cant difference between patients who died due to the
mono-agent sepsis and mixed sepsis (p>0.05).
APACHE II score remains reliable predictive data for
patient’s outcome9,16,17.
Identification of the sepsis’s source (focus) could be
very helpful, especially for the empirical therapy. There
is difference in therapeutic approach between intraabdo-
minal infection, pneumonia, (ventilator associated pneu-
monia – VAP) or catheter-associated infection18. The pre-
dominant source of sepsis in our surgical ICU was intra-
abdominal infection, followed by VAP.
We observed an increasing trend on A. baumannii
sepsis in contrast to MRSA sepsis.
Trampuz and Zimerlli19 suggested flucloxacillin +
amikacin like empirical therapy for unknown causative
agent. Paul-Erlich-Gesellschaft recommended cephalo-
sporine III generation and aminoglicoside20.
According to the antibiograms of the strains isolated
in our surgical ICU, we would suggest cephalosporine III
generation and ampicillin+sulbactam for the empirical
therapy of the sepsis with the unknown causative agent.
Since staphylococci were isolated from blood-culture in
some of our patients, in our opinion b-lactamase stable
penicillin (flucloxacillin) should be added to empirical
therapy15,21.
A.baumannii and P.aeruginosa often require adminis-
tration of carbapenems, due to their multiple antibiotic
resistence22–24. Carbapenems remains antibiotic of choice
for the treatment of infections caused by ESBL K. pneu-
moniae and E.coli. Vancomycin or linezolide we would
recommend for the therapy of sepsis caused byMRSA25,26.
Carbapenems and ampicillin+sulbactam could be con-
sidered as an option for the treatment of sepsis caused by
A. baumannii, which is a pathogen of growing impor-
tance nowadays.
Surveillance of antimicrobial susceptibility of the cau-
sative agents and their trends could be very useful to cre-
ate guidelines for the empirical therapy of the sepsis with
the unknown causative agent.
R E F E R E N C E S
1. FRIEDMAN G, SILVA E, VINCENT J, Crit Care Med, 26 (1998)
2078. — 2. ANGUS DC, LINDE-ZWIRBLE WT, LIDICKER J, CLER-
MONT G, CARCILLO J, PINSKY MR, Crit Care Med, 29 (2001) 1303. —
3. COHEN J, BRUN-BUISSON C, TORRES A, JORGENSEN J, Crit Care
Med, 32 Suppl. (2004) 466. — 4. DELLINGER RP, CARLET JM, MASUR
H, GERLACH H, CALANDRA T, COHEN T, GEA-BANACLOCHE J,
KEH D, MARSHALL JC, PARKER MM, RAMSAY G, ZIMMERMAN JL,
VINCENT JL, LEVY MM, Crit Care Med, 30 (2004) 536. — 5. ALBERTI
C, BRUN-BUISSON C, BURCHARDI H, MARTIN C, GOODMAN S, AR-
TIGAS A, SICIGNANO A, PALAZZO M, MORENO R, BOULME R, LE-
PAGE E, LE GALL R, Intensive Care Med, 28 (2002) 108. — 6. BOCHUD
PY, BONTEN M, MARCHETTI O, CALANDRA T, Crit Care Med, 32
Suppl. (2004) 495. — 7. IMAHARA SD, NATHENS AB, Cur Opin Crit
Care, 9 (2003) 286. — 8. VINCENT JL, SAKR Y, SPRUNG CL, RANIERI
VM, REINHART K, GERLACH H, MORENO R, CARLET J, LE GALL
JR, PAYEN D, Crit Care Med, 24 (2006) 344. — 9. KNAUS WA, DRAPER
EA, WAGNER DP, ZIMMERMAN JE, Crit Care Med, 13 (1985) 818. —
10. LAUPLAND KB, ZYGUN DA, DOIG CJ, BAGSHAW SM, SVENSON
LW, FICK GH, Intensive Care Med, 31 (2005) 213. — 11. BRUN-BUIS-
SON C, MESHAKA P, PINTON P, VALLET B, EPISEPSIS STUDY
GROUP, Intensive Care Med, 30 (2004) 580. — 12. WEYCKER D, AKH-
RAS KS, EDELSBERG J, ANGUS DC, ESTER G, Crit Care Med, 31
(2003) 2316. — 13. MIHALJEVI] LJ, MIHALJEVI] S, VASILJ I, ^AVA-
LJUGA S, SERDAREVI] F, SOLDO I, Bosn J Basic Med Sci, 7 (2007)
Lj. Mihaljevi} et al.: Therapy of Severe Sepsis, Coll. Antropol. 31 (2007) 4: 1093–1097
1096
Fig. 5. Major causative agents of sepsis. AB – Acinetobacter bau-
mannii, MRSA – Methicillin-resistant Staphylococcus aureus,
PA – Pseudomonas aeruginosa.
266. — 14. BUISING KL, THURSKY KA, BAK N, SKULL S, STREET A,
PRESNEILL JJ, Anaesth Intensive Care, 33 (2005) 571. — 15. GARNA-
CHO-MONTERO J, GARCIA-GARMENDIA JL, BARRERO-ALMODO-
VAR A, JIMENEZ-JIMENEZ FJ, PEREZ-PAREDES C, ORTIZ-LEYBA
C, Crit Care Med, 31 (2003) 2742. — 16. CHIAVONE PA, DOS SANTOS
SENS YA, Sao Paulo Med J, 121 (2003) 53. — 17. LE GALL JR, Intensive
Care Med, 31 (2005) 1618. — 18. JIMENEZ MF, MARSHALL JC, Inten-
sive Care Med, 27 Suppl. (2001) 49. — 19. TRAMPUZ A, ZIMMERLI W,
Schweiz Med Forum, 35 (2003) 811. — 20. ROSENTHAL EJ, Dtsch Med
Wochenschr, 127 (2002) 2435. — 21. LEONE M, BOURGOIN A, CAM-
BON S, DUBUC M, ALBANESE J, MARTIN C, Crit Care Med 31 (2003)
462. — 22. MICEK ST, LLOYD AE, RITCHIE DJ, REICHLEY RM, FRA-
SER VJ, KOLLEFMH, Antimicrob Agents Chemother, 49 (2005) 1311. —
23. CHOI JY, PARK YS, KIM CO, PARK YS, YOON HJ, SHIN SY, KIM
YA, SONG YG, YONG D, LEE K, KIM JM, Intern Med J, 35 (2005) 599.
— 24. DRENJAN^EVI] D, VRANE[ J, BEDENI] B, [AKI]-ZDRAV^E-
VI] K, Coll Antropol, 31 (2007) 221. — 25. GUILARDE AO, TURCHI
MD, MARTELI CMT, PRIMO MGB, J Hosp Infect, 63 (2006) 330. — 26.
HURLEY JC, Med J Aust, 176 (2002) 188.
Lj. Mihaljevi}
Department of Clinical andMolecular Microbiology, University Hospital Center Zagreb, Ki{pati}eva 12. Zagreb, Croatia
e-mail: slobodan.mihaljevic1@os.htnet.hr
MIKROBIOLO[KI NADZOR U KIRUR[KOJ JEDINICI INTENZIVNOG LIJE^ENJA KBC-a ZAGREB
– STO@ERNA-STUDIJA ZA SMJERNICE TERAPIJE TE[KE SEPSE
S A @ E T A K
Retrospektivnom studijom od 01.01.2003. godine do 31.12.2005. godine kod 74 bolesnika iz kirur{kog JIL-a KBC-a
Zagreb, pratili smo promjene prevalencije uzro~nika sepse koriste}i se pri tome njihovim klini~kim i mikrobiolo{kim
podacima. Cilj rada bio je odrediti smjernice za po~etnu antibiotsku terapiju te{ke sepse kod bolesnika u kirur{kom
JIL-u. Antimikrobna osjetljivost uzro~nika izoliranih iz hemokulture odre|ivana je metodom disk-difuzije prema CLSI
(Clinical Laboratory Standard Institution). APACHE II score kori{ten je za procjenu te`ine i ishoda bolesti. Mann-
Whitney i c2 test slu`ili su za statisti~ku obradu podataka, a kao granica statisti~ke zna~ajnosti uzet je p<0.05. Polimi-
krobna sepsa je bila posebno te`ak problem, kako za odre|ivanje definitivne antibiotske terapije, tako i za odre|ivanje
empirijske antibiotske terapije. Izolirano je deset razli~itih uzro~nika sepse, a naj~e{}i su: meticilin-rezistentni Staphy-
lococcus aureus (MRSA), Pseudomonas aeruginosa i Acinetobacter baumannii.Njihova prevalencija se mijenjala kroz te
tri godine, tako da je MRSA bila vode}i uzro~nik sepse u 2003. godini, P. aeruginosa u 2004. a A. baumannii u 2005. Kod
na{ih bolesnika, MRSA je pokazala dobru osjetljivost na vankomicin i linezolid, P. aeruginosa na ceftazidim i karbape-
neme, a A. baumannii na ampicilin+sulbaktam i karbapeneme.
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